Merck's Keytruda Shows Improved Metastasis-Free Survival In Melanoma Patients - Merck & Co (NYSE:MRK)

Merck & Co Inc (NYSE:MRK) announced data from Phase 3 KEYNOTE-716 trial of Keytruda (pembrolizumab) as adjuvant treatment for patients with resected stage IIB and IIC melanoma.

The trial has met its key secondary endpoint of distant metastasis-free survival (DMFS) at a prespecified interim analysis.
In the trial, adjuvant treatment with Keytruda demonstrated a statistically significant improvement in the endpoint of DMFS compared to placebo in these patients.
No new safety signals were observed.
At the interim analysis, treatment with Keytruda also continued to show an improvement in recurrence-free survival (RFS) compared to placebo.
As previously reported, KEYNOTE-716 met the primary endpoint of RFS at the first interim analysis, which supported FDA approval for this indication in December 2021.
In the U.S., Keytruda is approved for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB, IIC or III melanoma following complete resection.
Additional global regulatory submissions based on KEYNOTE-716 are ongoing.
Price Action: MRK shares are down 1.14% at $76.94 during the market session on the last check Monday.

MRKMerck & Co Inc

$112.77-%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.